Essers BAB, Tjan-Heijnen VCG, Severens JL, Novák A, Pompen M, Oron UH, Joore MA. Economic evaluation of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands. ISPOR 2008.

Essers BAB, Tjan-Heijnen VCG, Severens JL, Novák A, Pompen M, Oron UH, Joore MA. Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2-positive breast cancer in the Netherlands. Value in Health, submitted

Essers BAB, Tjan-Heijnen VCG, Severens JL, Novák A, Pompen M, Oron UH, Joore MA. Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2-positive breast cancer in the Netherlands. ISPOR 2008, oral presentation.

Goebbels A, Ament A, Novák A, Veraart C, Severens J. The implicit value of statistical life: estimates derived from public interventions implemented in the Netherlands. ISPOR 2008

Pompen M, Gok M, Novak A, Wuijtswinkel R, Postmus PE. Direct costs associated with the management of patients with unresectable advanced non-small cell lung cancer in the Netherlands. Lung Cancer, 2008

Goebbels A, Ament A, Novak A, Veraart C, Severens J. Estimating the implicit value of statistical life based on publicly financed interventions implemented in the Netherlands. Int J Technol Asees in Health Care, 2008,24(4):495-501.

Postma MJ, Novak A, Scheijbeler HWKFH et al. Cost-effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza; illustration for the Netherlands. PharmacoEconomics, 2007;25(6):497-509.

Velden van ME, Severens JL, Novak A. Economic Evaluations of healthcare programmes and decision-making. The influence of economic evaluations on different healthcare decision-making levels. PharmacoEconomics, 2005;23(11):1075-1082

Pompen M, Novak A, Gok M, Gyldmark M, Postmus PE, Afram C. Pharmacoeconomic analysis shows that erlotinib is cost-saving versus docetaxel and cost-effective versus best supportive care (BSC) in NSCLC. WCLC 2007

Pompen M, Novak A, Gok M, Gyldmark M. Pharmacoeconomic (PE) analysis of the treatment of non-small cell lung cancer (NSCLC) in the Netherlands demonstrates that erlotinib dominates docetaxel and is cost-effective over best supportive care (BSC).

Heinemann LAJ, Saad F, Zimmermann T, Novak A, Myon E, Badia X, Potthoff P, T'Sjoen G, Pöllänen P, Goncharow NP, Kim S, Giroudet C. The Aging Males' Symptoms (AMS) scale: Update and compilation of international versions. Health and Quality of Life Outcomes, 2003;1:15

Novák A, Brod M, Elbers J. Andropause & Quality of Life: findings from patient focus groups and clinical experts. Maturitas, 2002; 43: 231-237.

Novák A, de la Loge C, Abetz L. Development and validation of an acceptability and satisfaction questionnaire for a contraceptive vaginal ring, NuvaRing. PharmacoEconomics, 22(4):245-56, 2004.

Novák A, de la Loge C, Abetz L. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception, 2003;67(3):187-194.

Novák A, Brod M. Andropause, what it means to your patients. The Aging Male Conference, Berlin, February 2002.

Novák A, Abetz L, de la Loge C. Psychometric validation of contraceptive ring acceptability questionnaire. 8th Annual meeting of the International Society for Quality of Life Research, Amsterdam 2001.

Novák A, Abetz L, de la Loge C. Validation of NuvaRing acceptability questionnaire. 17th World Congress on Fertility and Sterility, Melbourne 2001.

Novák A, Abetz L, de la Loge C. Evaluation of NuvaRing acceptability in 14 countries. 17th World Congress on Fertility and Sterility, Melbourne 2001.